Unknown

Dataset Information

0

Cytosolic co-delivery of miRNA-34a and docetaxel with core-shell nanocarriers via caveolae-mediated pathway for the treatment of metastatic breast cancer.


ABSTRACT: Co-delivery of microRNAs and chemotherapeutic drugs into tumor cells is an attractive strategy for synergetic breast cancer therapy due to their complementary mechanisms. In this work, a core-shell nanocarrier coated by cationic albumin was developed to simultaneously deliver miRNA-34a and docetaxel (DTX) into breast cancer cells for improved therapeutic effect. The co-delivery nanocarriers showed a spherical morphology with an average particle size of 183.9?nm, and they efficiently protected miRNA-34a from degradation by RNase and serum. Importantly, the nanocarriers entered the cytosol via a caveolae-mediated pathway without entrapment in endosomes/lysosomes, thus improving the utilization of the cargo. In vitro, the co-delivery nanocarriers suppressed the expression of anti-apoptosis gene Bcl-2 at both transcription and protein levels, inhibited tumor cell migration and efficiently induced cell apoptosis and cytotoxicity. In vivo, the co-delivery nanocarriers prolonged the blood circulation of DTX, enhanced tumor accumulation of the cargo and significantly inhibited tumor growth and metastasis in 4T1-tumor bearing mice models. Taken together, the present nanocarrier co-loading with DTX and miRNA-34a is a new nanoplatform for the combination of insoluble drugs and gene/protein drugs and provides a promising strategy for the treatment of metastatic breast cancer.

SUBMITTER: Zhang L 

PROVIDER: S-EPMC5382875 | BioStudies | 2017-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2021-01-01 | S-EPMC7797688 | BioStudies
2019-01-01 | S-EPMC6538300 | BioStudies
2018-01-01 | S-EPMC6294246 | BioStudies
2019-01-01 | S-EPMC7032195 | BioStudies
1000-01-01 | S-EPMC6127092 | BioStudies
2014-01-01 | S-EPMC4332786 | BioStudies
2019-01-01 | S-EPMC6691925 | BioStudies
2018-01-01 | S-EPMC5914049 | BioStudies
2017-01-01 | S-EPMC5525751 | BioStudies
2020-01-01 | S-EPMC7332498 | BioStudies